e2f1 monoclonal antibody (Novus Biologicals)
Novus Biologicals is a verified supplier 
Novus Biologicals manufactures this product 
93
Structured Review
Novus Biologicals
e2f1 monoclonal antibody
E2f1 Monoclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f1+monoclonal+antibody/pmc11731210-335-1-5?v=Novus+Biologicals
Average 93 stars, based on 2 article reviews
E2f1 Monoclonal Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/e2f1+monoclonal+antibody/pmc11731210-335-1-5?v=Novus+Biologicals
Average 93 stars, based on 2 article reviews
e2f1 monoclonal antibody - by Bioz Stars,
2026-07
93/100 stars
Images
1) Product Images from "E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2"
Article Title: E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2
Journal: The Journal of Biological Chemistry
doi: 10.1016/j.jbc.2024.108027
Figure Legend Snippet: E2F1, E2F7 and MYBL2 are highly expressed in GC tissues and correlated with the prognosis of GC patients. A , mRNA levels of E2F1, E2F7 and MYBL2 in GC tissues and normal stomach tissues in TCGA dataset. B , mRNA levels of E2F1, E2F7, and MYBL2 evaluated by RT-qPCR (n = 3) in 30 GC tissues and their paracancerous tissues. C , representative pictures of IHC for E2F1, E2F7, and MYBL2 in clinical GC samples. Scale bars: 100 μm. D , scatter plots of E2F1, E2F7, and MYBL2 IHC staining scores on 30 paired clinical samples (N = 30, T = 30). E , E2F1 WBs for 30 paired clinical samples (N = 30, T = 30). In this paper, all numbers beneath each band ( i.e. 0.67) represent the relative intensities of the WB bands, normalized to the intensities of their corresponding internal reference bands. F , quantification of E2F1 protein levels in ( E ). Top : unpaired comparisons; Bottom : paired comparisons. G – I , Kaplan Meier curves for OS ( left column), FPS ( middle column) and PPS ( right column) for patients with GC having high or low mRNA levels of E2F1 ( G ), MYBL2 ( H ), and E2F7 ( I ). J , Kaplan-Meier OS curves for GC patients with high or low ratios of E2F1/E2F7 mRNA levels ( top panel) or E2F7/E2F1 mRNA levels ( bottom panel) corresponding to OS in GC patients. In this paper, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001, ns: not significant.
Techniques Used: Quantitative RT-PCR, Immunohistochemistry
Figure Legend Snippet: Effects of knockdown of E2F1, E2F7, or MYBL2 on GC cell proliferation and apoptosis. A , protein levels of E2F1, E2F7, and MYBL2 in 5 GC cell lines and one normal gastric mucosal cell line were evaluated by WB (n = 3). In this article, all cellular WB experiments were conducted with three independent biological replicates and the numerical values beneath each band were from the single blot shown. B , changes in protein levels after E2F1, E2F7 or MYBL2 knockdown in AGS and HGC-27 cells were evaluated by WB (n = 3). C , changes in cell growth curves drawn by cell counting after E2F1, E2F7, or MYBL2 knockdown in AGS and HGC-27 cells (n = 4). D , effects of E2F1, E2F7, or MYBL2 knockdown on the colony formation ability of AGS cells were assessed by a colony formation assay (n = 3). E , changes in cell cycle distributions after E2F1, E2F7, or MYBL2 knockdown in AGS cells were evaluated by flow cytometry (n = 3). F , changes in cellular proliferation of AGS cells after knockdown of E2F1, E2F7, or MYBL2 were assessed by EdU immunofluorescence staining (n = 3). Scale bar: 100 μm. G , changes in Ki67 and PCNA protein levels after E2F1, E2F7 or MYBL2 knockdown in GC cells were evaluated by WB (n = 3). H , changes in levels of apoptosis of AGS and HGC-27 cells after E2F1, E2F7, or MYBL2 knockdown were assessed by a TUNEL assay (n = 3). Positive control group (C+) cells were treated with DNase. Scale bar: 100 μm.
Techniques Used: Knockdown, Cell Counting, Colony Assay, Flow Cytometry, Immunofluorescence, Staining, TUNEL Assay, Positive Control
Figure Legend Snippet: E2F1 upregulates E2F7 and MYBL2, whereas E2F7 downregulates E2F1 and MYBL2 in GC cells. A , correlation between E2F1, E2F7, and MYBL2 mRNA levels in GC tissues from the TCGA dataset (n = 341). B , correlation between E2F1, E2F7, and MYBL2 mRNA levels in clinical GC samples (n = 30). C , changes in mRNA levels of E2F1, E2F7 and MYBL2 in AGS and HGC-27 cells following siE2F1 or siE2F7 transient transfections were evaluated by RT-qPCR (n = 3). D , changes in E2F1, E2F7 and MYBL2 protein levels in AGS and HGC-27 cells after siE2F1 ( left panel) and siE2F7 ( right panel) transient transfections were evaluated by WB (n = 3). E , quantification of E2F1, E2F7, and MYBL2 protein levels in AGS and HGC-27 cells after siE2F1 ( left panel in ( D )). F , quantification of E2F7, E2F1 and MYBL2 protein levels in AGS and HGC-27 cells after siE2F7 ( right panel in ( D )). G , changes in mRNA levels of MYBL2 and E2F7 after E2F1 overexpression in AGS and HGC-27 cells were evaluated by RT-qPCR (n = 3), and changes in protein levels of E2F1, MYBL2, E2F7, Ki67 and PCNA after E2F1 overexpression were evaluated by WB (n = 3). H , changes in mRNA levels of MYBL2 and E2F1 after E2F7 overexpression in AGS and HGC-27 cells were evaluated by RT-qPCR (n = 3), and changes in protein levels of E2F7, MYBL2, E2F1, Ki67 and PCNA after E2F7 overexpression were evaluated by WB (n = 3).
Techniques Used: Transfection, Quantitative RT-PCR, Over Expression
Figure Legend Snippet: Both E2F1 and E2F7 bind to the MYBL2 promoter and respectively activate and repress its transcription in GC cells. A , consensus binding sites of human E2F1 and E2F7. B , E2F1 and E2F7 binding to the MYBL2 and E2F1 promoters in HGC-27 cells was assessed by ChIP-qPCR (n = 3). The γ-tubulin promoter serves as a negative control. C , schematic diagram of the MYB-PGL3 plasmid containing the MYBL2 promoter sequence (−670 ∼ −170), with the E2F binding site (−212 ∼ −201) in the red box. D , changes of relative luciferase activities following overexpression of E2F1 or E2F7 in AGS and HGC-27 cells were evaluated by a dual-luciferase reporter assay (n = 3).
Techniques Used: Binding Assay, ChIP-qPCR, Negative Control, Plasmid Preparation, Sequencing, Luciferase, Over Expression, Reporter Assay
Figure Legend Snippet: E2F1 promotes GC cell proliferation by activating MYBL2, whereas E2F7 inhibits GC cell proliferation by repressing MYBL2. A , E2F1, MYBL2, Ki67, and PCNA protein levels in tet vector + tet shNC, tet OE-E2F1 + tet shNC, tet OE-E2F1 + shMYBL2, and tet vector + tet shMYBL2 groups were evaluated by WB (n = 3). B , cell growth curves were plotted using a cell counting assay (n = 4). C , changes in colony forming ability were evaluated by a colony formation assay (n = 3, (∗∗∗∗) p < 0.0001 vs. tet OE-E2F1 + tet shNC group, #### p < 0.0001 vs. tet OE-E2F1 + tet shMYBL2 group). D , cell cycle distributions were assessed by flow cytometry (n = 3, (∗∗) p < 0.01/(∗∗∗) p < 0.001 vs. tet OE-E2F1 + tet shNC group). E , cell proliferation levels were assessed by EdU immunofluorescence assay (n = 3, (∗∗) p < 0.01 vs. tet OE-E2F1 + tet shNC group). Scale bar: 100 μm. F , E2F7, MYBL2, Ki67 and PCNA protein levels in shNC + tet shNC, shE2F7 + tet shNC, shE2F7 + tet shMYBL2, and shNC + tet shMYBL2 groups were evaluated by WB (n = 3). G , cell growth curves were plotted using a cell counting assay (n = 4). H , colony-forming abilities were evaluated by a colony formation assay (n = 3, (∗∗∗∗) p < 0.0001 vs. shE2F7 + tet shNC group, # p < 0.05 vs. shE2F7 + tet shMYBL2 group). I , cell cycle distributions were assessed by flow cytometry (n = 3, (∗∗) p < 0.01/(∗∗∗) p < 0.001 vs. shE2F7 + tet shNC group). J , cell proliferation levels were assessed by EdU immunofluorescence assay (n = 3, (∗∗) p < 0.01 vs. shE2F7 + tet shNC group). Scale bar: 100 μm.
Techniques Used: Plasmid Preparation, Cell Counting, Colony Assay, Flow Cytometry, Immunofluorescence
Figure Legend Snippet: Knockdown of MYBL2 attenuates the tumor-promoting effects of E2F1 overexpression or E2F7 knockdown ex vivo . A , representative images of nude mice and tumors stripped from mice after the injection of AGS cells of four groups induced by doxycycline: tet vector + tet shNC, tet OE-E2F1 + tet shNC, tet OE-E2F1 + shMYBL2 and tet vector + tet shMYBL2 (n = 5). L: left . R: right . B , tumor weights of xenograft tumors in nude mice (n = 5). C , growth curves of tumor xenografts in nude mice (n = 5). D , Kaplan-Meier tumor-free curves in different groups of nude mice were presented (n = 5). E , representative images of H & E staining and Ki67 IHC staining in tumor samples. Scale bar: 50 μm. The percentages of positive cells were shown in the right panel (n = 5, (∗∗) p < 0.01 vs. tet OE-E2F1 + tet shNC group, # p < 0.05 vs. tet OE-E2F1 + tet shMYBL2 group). F , apoptosis of tumor samples was assessed by a TUNEL assay. Scale bar: 50 μm. The percentages of positive cells were shown in the right panel (n = 5, (∗∗∗∗) p < 0.0001 vs. tet OE-E2F1 + tet shNC group, ## p < 0.01 vs. tet OE-E2F1 + tet shMYBL2 group). G , representative images of nude mice and tumors stripped from mice after the injection of AGS cells of four groups induced by doxycycline: shNC + tet shNC, shE2F7 + tet shNC and shE2F7 + tet shMYBL2 and shNC + tet shMYBL2 (n = 5). L: left . R: right . H , tumor weights of tumor xenografts in ( G ) (n = 5). I , growth curves of tumor xenografts in ( G ) (n = 5). J , Kaplan-Meier tumor-free curves in different groups of nude mice ( G ) were presented (n = 5). K , representative images of H & E staining and Ki67 IHC staining in tumor samples in ( G ). Scale bar: 50 μm. The percentages of positive cells were shown in the right panel (n = 5, (∗∗∗∗) p < 0.0001 vs. shNC + tet shNC group, #### p < 0.0001 vs. shE2F7 + tet shMYBL2 group). L , apoptosis of tumor samples in ( G ) was assessed by a TUNEL assay. Scale bar: 50 μm. The percentages of positive cells were shown in the right panel (n = 5).
Techniques Used: Knockdown, Over Expression, Ex Vivo, Injection, Plasmid Preparation, Staining, Immunohistochemistry, TUNEL Assay
Figure Legend Snippet: E2F1 and E2F7 activate and repress MYBL2 to regulate cell growth through the PI3K/AKT pathway. A , oncogenic signaling pathways enriched by GSEA based on the differentially expressed genes between GC tissues with high MYBL2 expression levels and those with low MYBL2 expression levels. B , GSEA plot showing that the MYBL2-regulated genes correlate with the PI3K/AKT signaling pathway. C , the FGFR family genes among differentially expressed genes. D , PI3K, P-PI3K, AKT and P-AKT protein levels in tet vector + tet shNC, tet OE-E2F1 + tet shNC, tet OE-E2F1 + shMYBL2, and tet vector + tet shMYBL2 groups of AGS cells were evaluated by WB (n = 3, (∗∗∗) p < 0.001/(∗∗∗∗) p < 0.0001 vs. tet OE-E2F1 + tet shNC group). E , PI3K, P-PI3K, AKT and P-AKT protein levels in shNC + tet shNC, shE2F7 + tet shNC, shE2F7 + tet shMYBL2, and shNC + tet shMYBL2 groups of AGS cells were evaluated by WB (n = 3, (∗∗) p < 0.01/(∗∗∗∗) p < 0.0001 vs. shE2F7 + tet shNC group). F , PI3K, P-PI3K, AKT and P-AKT protein levels in shNC + Vector, shE2F1 + Vector, shE2F1 + OE-MYBL2, and shNC + OE-MYBL2 groups of HGC-27 cells were evaluated by WB (n = 3, (∗) p < 0.05 vs. shE2F1 + Vector group). G , PI3K, P-PI3K, AKT and P-AKT protein levels in Vector 1 + Vector 2, OE-E2F7 + Vector 2, OE-E2F7 + OE-MYBL2, and Vector 1 + OE-MYBL2 groups of HGC-27 cells were evaluated by WB (n = 3, (∗∗∗) p < 0.001 vs. OE-E2F7 + Vector two group). H , changes in MYBL2, PI3K, P-PI3K, AKT and P-AKT protein levels after MYBL2 overexpression treated with or without LY294002 in AGS cells were evaluated by WB (n = 3). I , changes in cell growth curves drawn by cell counting after MYBL2 overexpression treated with or without LY294002 in AGS cells (n = 4).
Techniques Used: Protein-Protein interactions, Expressing, Plasmid Preparation, Over Expression, Cell Counting
Fig. 1 C to highlight the specific distribution pattern). Scale bar: 50 μm. B , percentage of different E2F7 localization in adjacent tissues and GC tissues (λ 2 test, p < 0.01). C , nucleocytoplasmic distributions of E2F7 protein in 12 paired adjacent tissues and GC tissues were evaluated by WB. “∗” represented the specific band. D , statistics of the ratios of cytoplasmic E2F7 protein levels to nuclear E2F7 protein levels in ( C ). E , mRNA levels of E2F1 and MYBL2 in 30 GC samples with different nucleocytoplasmic distributions of E2F7 protein. F , representative images of IHC for Ki67 with different staining scores in GC tissues. Scale bars: 50 μm. G , statistics of Ki67 IHC staining scores in 30 GC samples with different nucleocytoplasmic distributions of E2F7 protein. " title="... GC cells correspond to lower mRNA levels of E2F1 and MYBL2 and lower protein levels of Ki67. ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Higher levels of nuclear E2F7 protein in GC cells correspond to lower mRNA levels of E2F1 and MYBL2 and lower protein levels of Ki67. A , nucleocytoplasmic distributions of E2F7 protein in adjacent tissues and GC tissues were evaluated by IHC staining (the N/C/GC panel reuses the bottom left quadrant from
Techniques Used: Immunohistochemistry, Staining
Figure Legend Snippet: Work model. E2F1 and E2F7 promote or inhibit cell proliferation in GC cells through direct transcriptional activation or repression of MYBL2 via PI3K/AKT signaling pathway, and form a negative feedback regulation in which E2F1 up-regulates E2F7 and E2F7 down-regulates E2F1. The nuclear protein levels of E2F7 determine the extent of its transcriptional repression and its impact on cell proliferation.
Techniques Used: Activation Assay
